- Report
- January 2021
- 147 Pages
China, Global
From €3000EUR$3,362USD£2,668GBP
- Report
- August 2023
- 88 Pages
Global
From €3500EUR$3,922USD£3,113GBP
- Report
- August 2021
- 112 Pages
Global
From €3200EUR$3,586USD£2,846GBP
- Report
- May 2021
- 221 Pages
Global
From €3549EUR$3,712USD£3,050GBP
- Report
- May 2023
- 147 Pages
Global
From €5735EUR$5,999USD£4,928GBP
- Report
- April 2023
- 147 Pages
Global
From €5735EUR$5,999USD£4,928GBP
Low Molecular Weight Heparin (LMWH) is a class of anticoagulant drugs used to prevent and treat thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. LMWH is a form of heparin, a naturally occurring anticoagulant, that has been modified to reduce its molecular weight and increase its bioavailability. LMWH is administered subcutaneously and has a longer half-life than unfractionated heparin, allowing for once-daily dosing. LMWH is also associated with fewer side effects than unfractionated heparin, making it a preferred treatment for cardiovascular diseases.
The LMWH market is a growing segment of the cardiovascular drugs market, with a wide range of products available. LMWH is used in a variety of clinical settings, including the prevention and treatment of thromboembolic disorders, the prevention of post-operative thrombosis, and the treatment of unstable angina and acute coronary syndrome.
Some of the major companies in the LMWH market include Sanofi, Pfizer, Bayer, and Bristol-Myers Squibb. Show Less Read more